zinc finger and BTB domain containing 42Genealiases: LCCS6 · ZNF925
Q-omics provides the consensus-scored ZBTB42 profile across patient tissues and cancer cell-line models. ZBTB42 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZBTB42 is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, ZBTB42 RNA expression shows 19,263 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, LIHC, and ACC as cancer lineages where ZBTB42 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBTB42 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBTB42 survival associations across molecular data types. ZBTB42 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBTB42 RNA expression–survival associations across cancer types. High ZBTB42 expression shows unfavorable associations in LGG and ACC, but favorable associations in KIRC, MESO, THCA and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZBTB42 RNA expression.
This table summarizes ZBTB42 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for ZBTB42. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBTB42 shows lower tumor expression in LUAD and KIRP and higher tumor expression in LIHC, BRCA, CHOL and STAD. The LIHC box plot shows higher ZBTB42 RNA expression in tumor versus normal tissue (log2 FC = +0.937, t-test p < 0.001).
This table shows molecular features associated with ZBTB42 in patient tissues and cancer cell lines. In patient samples, ZBTB42 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZBTB42 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
